Certis Oncology Announces Presentation Of Abstract at SNO Annual Meeting
Presentation to highlight predictive power of CertisAI™ approach to predict and test combination therapies for Glioblastoma Multiforme
San Diego, Calif. — November 15, 2023 – Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the acceptance of an abstract discussing a study evaluating AI-directed combination therapies for the treatment of glioblastoma multiforme (GBM), which will be presented at the Society for NeuroOncology (SNO) Annual meeting to be held in Vancouver, Canada November 16-19, 2023.
Glioblastoma multiforme (GBM) is a devastating primary brain cancer with nearly 15,000 new cases annually in the United States. The disease is typically treated with surgery, radiation therapy and temozolomide, but almost always recurs following treatment. This suggests the need for novel treatment approaches.
“Certis Oncology was founded to upend the status quo in cancer treatment, whereby one-size-first all therapeutic approaches continue to be used despite high failure rates in treating complex cancers like GBM,” said Peter Ellman, CEO of Certis Oncology. “This research aims to nudge the community towards using predictive artificial intelligence and functional testing to accelerate the use of combinatorial strategies and advance personalized cancer care.”
Abstract EXTH-61: A Multi-Targeted Approach to Evaluate Therapeutic Selection and Efficacy in Preclinical GBM Models
Poster session: Friday, November 17, 2023, 7:30-9:30 pm PDT
Abstract: Recent studies have suggested the utilization of combination therapy approaches for GBM patients to address temozolomide resistance. Certis developed a personalized, AI-based approach to predict and test combination therapies for GBM using tissue samples from an initial GBM incidence and recurrence following treatment. Accuracy of the predicted sensitives to treatment was then evaluated in vivo using both subcutaneously and orthotopically engrafted mouse models. Optical bioluminescence imaging (BLI) and MRI were used to assess therapeutic response of AI-predicted combination therapies and standard or care. Analysis confirmed a high degree of fidelity between the AI predictions and the observed analysis of the models thereby demonstrating the value of a novel, combinatorial platform for the assessment of therapeutic efficacy in GBM.
Click here to download the poster.
ABOUT CERTIS ONCOLOGY SOLUTIONS
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence™ — highly predictive therapeutic response data derived from AI-enabled insights and validated in advanced biological models of cancer. Our proprietary platform can help inform individual treatment decisions and accelerate the development of new cancer therapies. Learn more about clinically relevant orthotopic PDX models, focal radiation and more for your preclinical GBM studies.
MEDIA CONTACT
Certis Oncology Solutions
Kristein King
kking@certisoncology.com
573-818-4528